LY-3023414
- Generic Name
- LY-3023414
- Drug Type
- Small Molecule
- Chemical Formula
- C23H26N4O3
- CAS Number
- 1386874-06-1
- Unique Ingredient Identifier
- C88817F47Y
- Background
LY3023414 has been used in trials studying the treatment of Neoplasm, Solid Tumor, COLON CANCER, BREAST CANCER, and Advanced Cancer, among others.
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
- Conditions
- Breast CancerNeoplasm MetastasisColorectal Neoplasms
- Interventions
- First Posted Date
- 2014-04-28
- Last Posted Date
- 2020-04-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 167
- Registration Number
- NCT02124148
- Locations
- 🇺🇸
Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States
🇺🇸Tennessee Oncology PLLC, Nashville, Tennessee, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)
- Conditions
- Carcinoma, Non-small Cell Lung
- Interventions
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2020-09-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 142
- Registration Number
- NCT02079636
- Locations
- 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸Indiana Cancer Pavilion, Indianapolis, Indiana, United States
🇺🇸The West Clinic, Germantown, Tennessee, United States
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2014-02-06
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 198
- Registration Number
- NCT02057133
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Highlands Oncology Group - Duplicate 2, Rogers, Arkansas, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
A Study of LY3023414 in Participants With Advanced Cancer
- Conditions
- Metastatic Breast CancerNon-small Cell Lung CancerMalignant MesotheliomaAdvanced CancerMetastatic CancerNon-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2012-08-01
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 156
- Registration Number
- NCT01655225
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States
🇮🇹Azienda Ospedaliero - Universitaria S. Luigi Gonzaga, Orbassano, Torino, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.